• Chemed Corporation recently declared a quarterly cash dividend of US$0.70 per share payable on September 3, 2026, a US$0.10 increase from June’s payment, and reported second-quarter 2026 net income of US$67.7 million with higher earnings per share than a year earlier.
• This dividend hike marks Chemed’s 221st consecutive quarterly payout over 55 years as a public company, underlining a long-standing commitment to returning cash to shareholders alongside its ongoing share repurchase program and recent earnings growth.
• We’ll now examine how Chemed’s higher dividend, alongside its earnings momentum, may influence the existing investment narrative for the company.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Chemed Investment Narrative Recap

To own Chemed, you need to be comfortable with a story built on dependable cash generation from VITAS and Roto Rooter, but with meaningful exposure to Medicare reimbursement decisions and operational execution in both businesses. The latest dividend increase and stronger second quarter earnings do not materially change the near term focus on Medicare Cap risk at VITAS and demand and margin pressures at Roto Rooter, although they do highlight Chemed’s current earnings power and capital return capacity.

The most relevant recent development alongside the higher dividend is Chemed’s second quarter 2026 earnings report, which showed net income of US$67.7 million and higher earnings per share than a year earlier. Together with ongoing share repurchases, these results frame the current debate around whether recent earnings momentum can be sustained while the company continues to manage Medicare Cap exposure and addresses weaker residential trends and cost pressures at Roto Rooter.

Yet against this backdrop of higher dividends and improving earnings, the ongoing dependence on Medicare reimbursement terms is something investors should be aware of, because...

Chemed's narrative projects $3.1 billion revenue and $397.9 million earnings by 2029. This requires 6.3% yearly revenue growth and a $122.9 million earnings increase from $275.0 million today.

Uncover how Chemed's forecasts yield a $501.50 fair value, a 9% downside to its current price.

Exploring Other Perspectives

While the consensus narrative focuses on steady cash returns, the most optimistic analysts were already assuming revenue near US$3.1 billion and earnings around US$417.5 million by 2029, so this latest dividend hike and earnings beat may eventually push those bullish expectations and the underlying hospice growth assumptions in either direction.

Explore 3 other fair value estimates on Chemed - why the stock might be worth as much as 26% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Chemed research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Chemed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Chemed's overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.